支气管哮喘患者血清IP-10水平及吸入沙美特罗替卡松对其影响的研究

IP-10 levels in asthmatic patients and changes after salmeterol and fluticasone propionate powder inhalation

目的通过观测支气管哮喘(简称哮喘)患者与正常人的血清干扰素诱导蛋白-10(IP-10)水平以及哮喘患者吸入沙美特罗替卡松后血清IP-10的变化情况,初步探讨IP-10在哮喘发病机制中的作用。方法 16例哮喘患者分别于治疗前及吸入沙美特罗替卡松治疗30d后检测肺功能、抽取静脉血测定IP-10、INF-γ(酶联免疫吸附试验法)及外周血嗜酸粒细胞、淋巴细胞计数,并进行比较;8例健康体检者仅抽取静脉血测定IP-10、INF-γ水平并与哮喘组相比较。结果哮喘组血清IP-10水平高于正常组(P<0.05)而INF-γ水平低于正常组(P<0.01),治疗1个月后前者明显下降(P<0.05)而后者显著升高(P<0.01),并与正常组水平差异无统计学意义(P>0.05);哮喘组治疗1个月后FEV1%pred、PEF%pred较治疗前升高(P<0.01),嗜酸粒细胞计数均较治疗前降低(P<0.05);血清IP-10水平与FEV1%pred水平呈中度负相关(P<0.05)。结论 IP-10参与了哮喘的发病,进一步提示哮喘发病机制的复杂性;哮喘患者吸入激素联合长效β2受体激动剂治疗后可显著降低血清IP-10水平。

Objective To investigate interferon-inducible protein-10 （IP-10）＇ s role in the pathogenesis of asthma we observed serum IP-10 levels in asthmatic patients and healthy persons, and examined the changes of serum IP-10 in asthmatic patients inhaled salmeterol and fluticasone propionate powder. Methods 16 asthmatic patients inhaled salmeterol and fluticasone propionate powder for a month were detected their lung functions, peripheral blood eosinophils and lymphocytes counts, and serum IP-10, INF-T （using enzyme-linked immune assay）, then compared with each other. Eight healthy volunteers just measured serum IP-10, INF7 and compared with the asthma group. Results Serum IP-10 levels in asthmatic patients before treatment were significantly higher than healthy volunteers （ P〈0.05） and serum INF-T levels were significantly lower than healthy volunteers （ P〈 0.01）. After 1 month treatment the levels of IP-10 decreased （ P d0.05） while INF-T increased （ P〈0.01） ,and there were no significant difference between asthmatic patients and healthy volunteers （ P〈0.05）. After treatment, the FEV1 %pred and PEF%pred of asthmatic patients increased （ P 〈0.01） ,while the eosinophils counts decreased （ P〈0.05）. Serum IP-10 levels correlated negatively with FEV1%pred for asthmatic patients （ P 〈0.05）. Conclusions IP-10 may be involved in the pathogenesis of asthma and further indicated the complexity of the pathogenesis of asthma. Treatment with inhaled glucocorticosteroids and long-acting inhaled β2 agonists can significantly reduce serum IP-10 level in asthma.